Digital voice recordings contain valuable information that can indicate an individual’s cognitive health, offering a non-invasive and efficient method for assessment.
Coherus and Junshi’s PD-1 inhibitor approved for nasopharyngeal carcinoma – Pharmaceutical Technology
Coherus licensed Loqtorzi from Junshi for marketing in the US and Canada in February 2021. Image Credit: Prostock-studio / Shutterstock. The US Food and Drug